Yen-Shen Lu is currently Clinical Professor of Medicine at the National Taiwan University College of Medicine, as well as Division Chief of Medical Oncology at Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Dr Lu graduated from the Chinese Medical College, Taichung, in 1992 and obtained his PhD from the National Taiwan University, Taipei, Taiwan, in 2006. During 2005-2006. Dr. Lu has extensive experience as a translational researcher, clinical trial initiator, protocol writer, clinical trial steering committee member/chair, and as a principal investigator or co-principal investigator for more than 90 clinical trials, with particular focus on targeted agents in metastatic breast cancer, especially ER+ disease and breast cancer with brain metastases. He was the co-chair of steering committee of MONALEESA-7 trial, and chair of steering committee of BYOND and RIGHT Choice trials. He is currently lead member of Asian Breast Cancer Cooperative Group, and member of Scientific Committee of TRIO (Translational Research in Oncology). He has received the Scholar in Training Award at the 92nd Annual Meeting of the American Association Cancer Research in 2001, Chien-Tien Hsu's Outstanding Cancer Research Award in 2019, Mistry of Science and Technology Outstanding Research Award in 2020, National Taiwan University Hospital Outstanding Research Award in 2020. Additionally, Dr. Lu led a series of studies focusing on young female breast cancer, regarding to the epidemiology, biology, and genetic differences between East and Western. He is first or corresponding author of articles published in many high impact peer-reviewed international journals, including New England Journal of Medicine, Lancet Oncology, Journal of National Cancer Institute, and Journal of Clinical Oncology.